General Transistor Corp. – Trademark Portfolio
Entity Type: 03
General Transistor Corp. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 30 (Staple Foods) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VITAMIN FRIENDS. The owner is based in Los Angeles, CA.
300 Beethoven St.
Los Angeles, CA 90066
Showing of trademarks Trademarks
Trademark Classifications
General Transistor Corp.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does General Transistor Corp. have?
General Transistor Corp. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 3 cancelled.
What trademark classes does General Transistor Corp. file in?
General Transistor Corp. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 30 (Staple Foods), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are General Transistor Corp.'s most well-known trademarks?
General Transistor Corp.'s registered trademark portfolio includes well-known marks such as VITAMIN FRIENDS. These are among 1 currently registered trademark in the portfolio.
What is General Transistor Corp.'s trademark registration success rate?
General Transistor Corp. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.